Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UJX4
UPID:
APC5_HUMAN
Alternative names:
Cyclosome subunit 5
Alternative UPACC:
Q9UJX4; E9PFB2; Q8N4H7; Q9BQD4
Background:
Anaphase-promoting complex subunit 5, also known as Cyclosome subunit 5, plays a pivotal role in cell cycle regulation. It is a component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase. This complex is crucial for controlling progression through mitosis and the G1 phase of the cell cycle by mediating ubiquitination and subsequent degradation of target proteins. It primarily facilitates the formation of 'Lys-11'-linked polyubiquitin chains, with lesser activity towards 'Lys-48'- and 'Lys-63'-linked chains.
Therapeutic significance:
Understanding the role of Anaphase-promoting complex subunit 5 could open doors to potential therapeutic strategies.